Effects of Aging on Primary and Secondary Vaccine Responses (NCT03312699) | Clinical Trial Compass
CompletedPhase 1
Effects of Aging on Primary and Secondary Vaccine Responses
United States54 participantsStarted 2017-09-19
Plain-language summary
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study.
✓. Prior participant in either the Ellison cohort or another Stanford vaccine study with archived samples.
✓. Male or female, aged 18-40 years or 65 years and older.
✓. In good general health as evidenced by medical history.
Exclusion criteria
✕. Prior off-study vaccination with the current season influenza vaccine for influenza vaccinations.
✕. Allergy to egg or egg products
✕. Allergy to vaccine components, including thimerosal
✕. Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
✕. Receipt of blood or blood products within the past 6 months of any study vaccination or planned receipt of blood products prior to completion of Day 28 post-immunization visit.
✕. Receipt of inactivated vaccine 14 days prior to study vaccination or planned vaccination prior to Day 28 after study vaccination.
✕. Receipt of live, attenuated vaccine within 60 days of study vaccination or planned vaccination prior to Day 28 after study vaccination.
✕. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or planned blood donation prior to Day 28 after study vaccination.